Trump and HHS Director Link Tylenol to Autism Risks
President Donald Trump, along with Health and Human Services (HHS) Director Robert F. Kennedy Jr., recently announced a concerning connection between the prenatal use of Tylenol, or acetaminophen, and an increased risk of autism in children.
It’s interesting—though perhaps alarming—that while pregnant women are still advised to take Tylenol during instances of a “very high fever,” Trump remarked that he prefers not to complicate the situation. After making that comment, he let Kennedy take over the speaking duties.
The news had immediate financial fallout; shares of Kenvue, Tylenol’s manufacturer, dropped over 7%. As of the latest figures, Kenvue’s share price stood at $16.97, marking a decline since the previous day’s close.
During the press conference at the White House, Trump was joined by 17-year-old Mehmet Oz, as well as Jay Bhattacharya of NIH and other notable figures, as they prepared to discuss the implications of Tylenol use during pregnancy in relation to autism.
Trump, who had previously mentioned that this announcement could be one of the most significant medical insights in U.S. history, spoke emotionally about finding answers related to autism. He made a comparison to excessive vaccinations, suggesting that it’s akin to “shooting a horse.” It’s a provocative analogy, to say the least.
“I really think this will be one of the most important press conferences I’ve ever had,” Trump expressed, reflecting a mix of hope and urgency.
Kennedy took his turn at the podium, capturing attention before diving into the prevalent concerns about autism. He criticized past approaches, stating that HHS has primarily focused on politically safe research, neglecting the obvious environmental factors—as he likened it to studying genetics in lung cancer without considering smoking. He stressed the importance of moving towards evidence-based medicine, promising a more transparent approach and a commitment to understanding the roots of autism.
Kennedy also highlighted the alarming increase in autism rates since the year 2000, attributing the condition to various factors, including potential links between Tylenol and ADHD as well as liver toxicity in children.
What’s Next
- The FDA plans to update recommendations for leucovorin, initially for children with brain folate deficiency, marking a significant step in acknowledging treatments related to autism-like symptoms.
- Changes to acetaminophen’s safety label are also on the horizon, aimed at informing both medical providers and the public about the possible risks tied to its use during pregnancy.
The administration will advise healthcare providers to prescribe the lowest effective dose for the shortest period when treatment is necessary.
Autism, or Autism Spectrum Disorder (ASD), encompasses a range of neurodevelopmental conditions that impact communication, interaction, and perception. The variations—ranging from mild to severe—are particularly important to note.
Scientific Community’s Response
Reactions from the scientific community indicate division on this issue. Some studies highlight strong links between prenatal exposure to acetaminophen and neurodevelopmental disorders like ASD and ADHD. However, contrasting research, including a comprehensive study involving over two million children in Sweden, found no causal relationship. The mixed evidence makes the debate complex and ongoing.
